Achilles Therapeutics PLC (ADR)

General ticker "ACHL" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $39.9M (TTM average)

Achilles Therapeutics PLC (ADR) follows the US Stock Market performance with the rate: 38.6%.

Estimated limits based on current volatility of 1.2%: low 1.47$, high 1.50$

Factors to consider:

  • Earnings expected soon, date: 2025-04-03 bmo
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.51$, 1.47$]
  • 2024-12-30 to 2025-12-30 estimated range: [0.65$, 1.73$]

Financial Metrics affecting the ACHL estimates:

  • Negative: Non-GAAP EPS, $ of -1.74 <= 0.04
  • Negative: Operating profit margin, % of -1.00 <= 0
  • Negative: Operating cash flow per share per price, % of -1.21 <= 0.15
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -0.25 <= 0.03

Similar symbols

Short-term ACHL quotes

Long-term ACHL plot with estimates

Financial data

YTD 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM
Operating Expenses $78.38MM $75.25MM
Operating Income $-78.38MM $-75.25MM
Non-Operating Income $7.32MM $6.08MM
R&D Expense $57.26MM $67.65MM
Income(Loss) $-71.06MM $-69.17MM
Taxes $0.11MM $0.49MM
Profit(Loss)* $-71.18MM $-69.39MM
Stockholders Equity $197.04MM $142.37MM
Inventory $4.62MM $0.00MM
Assets $220.36MM $161.46MM
Operating Cash Flow $-59.53MM $-48.45MM
Capital expenditure $7.51MM $1.10MM
Investing Cash Flow $-7.51MM $-1.10MM
Financing Cash Flow $0.00MM $0.01MM
Earnings Per Share** $-1.82 $-1.74
Ordinary share to ADR 1.00x 1.00x

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.